Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Content
    • Current
    • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Persistence of Primary MALT Lymphoma of the Urinary Bladder after Rituximab with CHOP Chemotherapy and Radiotherapy

JASNA BACALJA, MONIKA ULAMEC, DUJE RAKO, LIDIJA BOŠKOVIĆ, DAVOR TRNSKI, EDUARD VRDOLJAK and BOŽO KRUŠLIN
In Vivo July 2013, 27 (4) 545-549;
JASNA BACALJA
1Department of Pathology, Dubrava University Hospital, Zagreb, Croatia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jasnabacalja@yahoo.com
MONIKA ULAMEC
2School of Medicine, University of Zagreb, Zagreb, Croatia
3Ljudevit Jurak Department of Pathology, Sestre Milosrdnice Clinical Hospital Center, Zagreb, Croatia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DUJE RAKO
4Department of Urology, Dubrava University Hospital, Zagreb, Croatia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LIDIJA BOŠKOVIĆ
6Department of Oncology, Clinical Hospital Center, Split, Croatia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DAVOR TRNSKI
5Department of Urology, Sestre Milosrdnice Clinical Hospital Center, Zagreb, Croatia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EDUARD VRDOLJAK
6Department of Oncology, Clinical Hospital Center, Split, Croatia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BOŽO KRUŠLIN
2School of Medicine, University of Zagreb, Zagreb, Croatia
3Ljudevit Jurak Department of Pathology, Sestre Milosrdnice Clinical Hospital Center, Zagreb, Croatia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

We present a case of a patient with primary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the urinary bladder that persisted after chemotherapy, immunotherapy and radiotherapy. Case Report: A 48-year-old male underwent a routine ultrasound examination. A tumour mass in the urinary bladder was found and a transurethral biopsy was performed. Pathohistological examination revealed MALT lymphoma. Results of computed tomographic scan, positron emission tomography scan and bone marrow biopsy defined the tumour as primary malignant lymphoma of the urinary bladder. The patient received eight cycles of chemo-immunotherapy (CHOP) and radiotherapy. Five months after therapy, there is a partial radiological remission, but with metabolic progression of the tumour. To our knowledge, this is the first case of MALT lymphoma of the urinary bladder with chemo-immunotherapy and radiotherapy resistance.

  • MALT lymphoma
  • urinary bladder
  • chemotherapy
  • rituximab
  • CHOP
  • Received May 6, 2013.
  • Revision received June 8, 2013.
  • Accepted June 10, 2013.
  • Copyright © 2013 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
View Full Text
PreviousNext
Back to top

In this issue

In Vivo: 27 (4)
In Vivo
Vol. 27, Issue 4
July-August 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Persistence of Primary MALT Lymphoma of the Urinary Bladder after Rituximab with CHOP Chemotherapy and Radiotherapy
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
13 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Persistence of Primary MALT Lymphoma of the Urinary Bladder after Rituximab with CHOP Chemotherapy and Radiotherapy
JASNA BACALJA, MONIKA ULAMEC, DUJE RAKO, LIDIJA BOŠKOVIĆ, DAVOR TRNSKI, EDUARD VRDOLJAK, BOŽO KRUŠLIN
In Vivo Jul 2013, 27 (4) 545-549;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Persistence of Primary MALT Lymphoma of the Urinary Bladder after Rituximab with CHOP Chemotherapy and Radiotherapy
JASNA BACALJA, MONIKA ULAMEC, DUJE RAKO, LIDIJA BOŠKOVIĆ, DAVOR TRNSKI, EDUARD VRDOLJAK, BOŽO KRUŠLIN
In Vivo Jul 2013, 27 (4) 545-549;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Case Report
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Three-month Prostate-specific Antigen Level After Androgen Deprivation Therapy Predicts Survival in Patients With Metastatic Castration-sensitive Prostate Cancer
  • A Finnish Version of RAND-36-Item Health Survey Versus Structured Interview 8 Years Postoperatively
  • Cytotoxic T-lymphocyte Antigen-4 (CTLA-4) Gene Polymorphism (rs3087243) Is Related to Risk and Survival in Patients With Colorectal Cancer
Show more Clinical Studies

Similar Articles

Keywords

  • MALT lymphoma
  • urinary bladder
  • chemotherapy
  • rituximab
  • CHOP
In Vivo

© 2021 In Vivo

Powered by HighWire